BAFFR

BAFFR

BAFFR Overview

Molecule Name
B-cell activating factor receptor
Synonyms
BAFFR,TNFRSF13C,BROMIX,CD268,CVID4,prolixin,BAFF-R
Drug Development Progress
Drugs in Clinical Trials14
Approved Drugs0
Highest Development StageNDA/BLA
Target Synonym
BAFFR,B Cell-Activating Factor Receptor,Prolixin,BROMIX,CD268,Tumor Necrosis Factor Receptor Superfamily, Member 13C,Tumor Necrosis Factor Receptor Superfamily Member 13C,BR3,CVID4,CD268 Antigen,BAFF Receptor,B-Cell Activation Factor Receptor,BAFF-R,TNF Receptor Superfamily Member 13C,BLyS Receptor 3,B-Cell-Activating Factor Receptor,TNFRSF13C
Background
BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.

BAFFR Product List

Species
  • Human(6)
  • Mouse(3)
  • Cynomolgus(2)
  • Rat(1)
Tag
  • His Tag(5)
  • Fc Tag(3)
  • Fc Tag & Avi Tag(2)
  • His Tag & Avi Tag(1)
  • Llama IgG Fc Tag(1)
Host
  • HEK293(12)
Conjugate
  • Unconjugated(8)
  • Biotin-labeled(3)
  • PE Labeled(1)
Grade
  • RUO(12)
Low Endotoxin
  • Yes(2)
  • No(10)
You Have Viewed 1-10 Of 12 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Antibody Project Trading Platform

Project NameProject StageMolecule TypeMolecule SourceDisease AreaIndication
BAFFR&CD3 BsAb - 01PCCBispecificHumanized Mouse,NanobodyHematological Malignancy,AutoImmunityBlood tumor,Autoimmune disease
Project Stage
PCC
Molecule Type
Bispecific
Molecule Source
Humanized Mouse,Nanobody
Disease Area
Hematological Malignancy,AutoImmunity
Indication
Blood tumor,Autoimmune disease
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Fully Human BAFF-R Chimeric Antigen Receptor T-Cell (Taihe Chunyu)Phase 2 ClinicalHebei Tahoe Chunyu Biotechnology Co Ltd
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Waldenstrom Macroglobulinemia
Details
Anti-BAFFR CAR T therapy(The General Hospital Of Tianjin Medical University)BAFFR CARTPhase 2 ClinicalThe General Hospital Of Tianjin Medical University
Myasthenia Gravis; Myositis; Neuromyelitis Optica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Details
ESG-206ESG-206Phase 2 ClinicalShanghai Escugen Biotechnology Co Ltd
Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Neoplasms; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome
Details
dual anti-CD19/anti-BAFF CAR T-cell therapy (Shanghai YaKe Biotechnology/Zhejiang University)Phase 1 ClinicalShanghai Yake Biotechnology Co Ltd
Autoimmune Diseases; Dermatomyositis; Lupus Erythematosus, Systemic; Nephritis; Neuromyelitis Optica; Scleroderma, Systemic
Details
SSS-68SSS68; SSS-68Phase 1 ClinicalShenyang Sunshine Pharmaceutical Co Ltd
Glomerulonephritis, IGA
Details
BAFF-R CAR-T cells therapy (Topcel-KH Pharmaceutical)Phase 1 ClinicalJiangsu Topcel-KH Pharmaceutical Co Ltd
Lymphoma, B-Cell
Details
BAFFR CAR-T cell therapy (Bio-gene Technology)Phase 1 ClinicalGuangzhou Bio-Gene Technology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
LY-4152199LY-4152199; LY4152199Phase 1 ClinicalEli Lilly And Company
Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin
Details
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells therapy(Mayo Clinic)MC10029; MC-10029Phase 1 ClinicalMayo Clinic
Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell
Details
CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang University
Autoimmune Diseases; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Details
KD-6005KD-6005; KD6005Phase 1 ClinicalShanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co Ltd
Arthritis, Rheumatoid
Details
AritinerceptAUR-200; AUR200Phase 1 ClinicalThunderbolt Pharma Inc
Autoimmune Diseases
Details
JH-013JH-013Phase 1 ClinicalBiotech Pharmaceuticals Co Ltd
Arthritis, Rheumatoid; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Sjogren's Syndrome
Details
BAFFR-CAR T cell therapy (PeproMene Bio)PMB-101; PMB-CT01Phase 1 ClinicalCity Of Hope National Medical Center, PeproMene Bio Inc
Leukemia, Biphenotypic, Acute; Lymphoma, B-Cell; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Details
Customer Reviews